K-numberK251014
Device nameAPRO 45 Catheter
ApplicantAlembic, LLC
Product codeDQY
Device classClass II
Decision dateMay 1, 2025
DecisionSubstantially Equivalent
Regulation870.1250
AI Summary extracted from FDA summary PDF · never regenerated
Intended use

The APRO 45 Catheter is a single-lumen, braid and coil reinforced catheter designed to facilitate insertion and guidance of interventional devices into peripheral and neurovascular blood vessels. It features a hydrophilic coating on the distal segment, a radiopaque marker for fluoroscopic visualization, and is provided sterile and single-use with an introducer sheath.

Technological characteristics

The APRO 45 Catheter is smaller than the predicate (0.045 inch inner diameter vs. 0.055 inch; 0.060 inch proximal outer diameter vs. 0.066 inch). It uses a PTFE/Pebax composite liner instead of PTFE/Tecoflex, polyether block amide extrusions instead of thermoplastic polyurethanes, offers multiple effective lengths (115–160 cm vs. 125–137 cm), and has an extended 1-year shelf life versus 6 months. Core design elements—hub, adhesive, braid/coil, marker band, coating, tip shape, sterilization method, and accessories—remain identical to the predicate APRO 55 Catheter.

Test standards cited

ISO 10555-1 (catheters—sterility, burst pressure, liquid leakage, corrosion resistance); ISO 80369-7 (small-bore connectors); ISO 11135 (ethylene oxide sterilization and sterility assurance level validation); ISO 10993-1 (biocompatibility evaluation and risk management).

Substantial equivalence argument

The APRO 45 differs from the predicate primarily in dimensional scaling and minor material substitutions in the liner and extrusion layers. All bench performance tests—including kink resistance, torque strength, burst pressure, tensile strength, delivery/retrieval forces, and simulated use with stent retrievers—met acceptance criteria comparable to or equal to the predicate. Biocompatibility testing confirmed non-sensitizing, non-irritant, non-cytotoxic, and non-thrombogenic properties. These dimensional and material changes do not alter the fundamental operating principle (over-the-wire catheterization for device guidance and retrieval) or intended use, and the smaller lumen is a predictable consequence of the reduced diameter that does not introduce new safety concerns.

Extracted by AI from the official FDA summary PDF →
Source

View the full FDA submission: accessdata.fda.gov

Researching this as a predicate?
Want a transparent AI-ranking score, AI-discovered related predicates, ongoing safety and warning-letter monitoring, full predicate chain lineage, and a drafted SE rationale — all saved to your own project? That's what an account adds.
Start free trial →

Everything you need for a 510(k) submission. Nothing you don't.

14-day free trial. No setup. Cancel anytime.

Start free trial →
Building an AI or ML-enabled device? Predicate search, PCCP tracking, and AI-specific FDA intelligence — built exclusively for AI/ML devices. Try AIFDA Intel →